Patent ID: 9248139
Filing Date: 2016-02-02
CPC Classification: A61K,A61P,C07D,C07F

Claim Text:
1. A process for the production of a formulation of HPMC and a crystalline HIV attachment inhibitor piperazine tris salt prodrug compound, wherein said compound is 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine, said process comprising: a) dissolving said prodrug compound in water to form a solution; b) adding a first quantity of a first anti-solvent to said solution, wherein said first anti-solvent is acetone; c) dispersing a first quantity of HPMC in said solution; d) adding a second quantity of said first anti-solvent to said solution; e) dispersing a second quantity of HPMC in said solution; and f) adding a second anti-solvent to said solution so as to crystallize said compound on the inside and on the surface of said HPMC and thereby form said formulation, wherein said second anti-solvent is a combination consisting essentially of acetone and isopropyl acetate (IPAC).